These risks
and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral
and other programs; the risk that private
and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy
and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks
and rebates due to ongoing contracts
and future negotiations with commercial
and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments
and geographic regions
and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal
and state grant cycles which may not mirror patient demand
and may cause fluctuations in Gilead's earnings; market share
and price erosion caused by the introduction of generic versions of Viread
and Truvada, an uncertain global macroeconomic environment;
and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to
initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers
and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop
and commercialize cell therapies utilizing the zinc finger nuclease technology platform
and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new
and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians
and patients may not see advantages of these products over other therapies
and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology
and inflammation / respiratory programs;
safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620
and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues
and pre-tax earnings;
and other risks identified from time to time in Gilead's reports filed with the U.S. Securities
and Exchange Commission (the SEC).